Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
John Koo MD

John Koo MD

Professor of Dermatology, UCSF School of Medicine; Vice-Chairman, Department of Dermatology, UCSF Medical Center; Co-Director, Psoriasis Skin and Treatment Center; Director, Phototherapy Unit, Clinical Research Unit, and Psychodermatology Clinic, San Francisco, California

Dr. John Koo is a board certified physician in both psychiatry and dermatology. He is one of the pioneers of psychodermatology, a sub-specialty of dermatology in the United States. He is professor and vice chairman of the department of dermatology at the University of California, San Francisco Medical Center. He is also the director of the UCSF Psoriasis Treatment Center, Phototherapy Unit, Clinical Research Unit, and Psychodermatology Clinic. He has more than 300 peer-reviewed publications. He has also been named “Best Doctor in America” year after year for more than a decade. His other areas of expertise include psoriasis, eczema, phototherapy, biologics, topical therapy of psoriasis, and oral immunosuppressants. Dr. Koo has lectured widely on these topics both domestically and internationally. 

Disclosures

Dr. John Koo is a speaker for AbbVie and Leo. Dr. Koo conducts research for Amgen, Janssen, Novartis, Photomedex, Galderma, Pfizer, and Merck. Dr. Koo has no stocks, employment, or board memberships with any pharmaceutical company.

Recent Contributions to PracticeUpdate:

  1. Psycholag — A New Term Describing the Delay Between Physical and Psychological Improvement in Patients With Skin Disease
  2. Efficacy of Self-Help Habit Replacement in Individuals With Body-Focused Repetitive Behaviors
  3. Treatment Strategies for Common Psychodermatologic Disorders
  4. Associations of Internalized Skin Bias With Age, Adverse Psychopathology, and HRQOL in Patients With Hidradenitis Suppurativa
  5. Stimulant Use in Psychocutaneous Disorders
  6. Real-World Data on Subcutaneous vs Oral Methotrexate in Psoriasis
  7. Differential Effects of Biologics on Psoriasis-Related Vascular Inflammation and Risk of Thrombosis
  8. The Utility of Subcutaneous Methotrexate for Chronic Plaque Psoriasis in a Real-World Setting
  9. Opioid, Alcohol, and Cannabis Misuse Among Patients With Hidradenitis Suppurativa
  10. Depressive Symptoms, Depression, and the Effect of Biologic Therapy Among Patients With Psoriasis

Most Read This Week

Recently Updated